US2007141044A1PendingUtilityA1

Method for treating cancer patients undergoing chemotherapy

61
Individually held — no corporate assignee on recordPriority: Jun 5, 2003Filed: Jun 4, 2004Published: Jun 21, 2007
Est. expiryJun 5, 2023(expired)· nominal 20-yr term from priority
Inventors:Shalom Z. Hirschman
A61K 31/00A61K 38/012A61K 31/7105A61K 45/06A61P 7/00A61P 35/00A61P 7/06A61P 43/00A61K 38/01A61K 38/16
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for treating cancer patients undergoing chemotherapeutic treatments by administering Product R, a peptide-nucleic acid preparation, is disclosed.

Claims

exact text as granted — not AI-modified
1 . A method of maintaining or increasing the number of white blood cells in a cancer patient undergoing chemotherapeutic treatment for cancer, comprising administering to said patient an effective treatment amount of Product R.  
     
     
         2 . The method of  claim 1  in which said cancer patient does not have basal cell carcinoma or a cancer of a lymphocytic cell.  
     
     
         3 . The method of  claim 1  or  2  in which said administering is not subcutaneous, intralesional, topical or by injection.  
     
     
         4 . The method of  claim 1  in which said administering to said patient is parenterally and said Product R is in a sterile injectable formulation.  
     
     
         5 . The method of  claim 4  in which said cancer patient does not have basal cell carcinoma or a cancer of a lymphocytic cell.  
     
     
         6 . The method of  claim 1  in which an effective treatment amount of Product R is in a range from about 5 microliters to about 40 microliters per kilogram of body weight per day in a sterile formulation.  
     
     
         7 . The method of  claim 1  in which an effective treatment amount of Product R is in a range from about 10 microliters to about 25 microliters per kilogram of body weight per day in a sterile formulation.  
     
     
         8 . The method of  claim 1  in which an effective treatment amount of Product R is about 30 microliters per kilogram of body weight per day in a sterile injectable formulation for about one week, followed by about 15 microliters per kilogram of body weight per day in a sterile formulation.  
     
     
         9 . A method of maintaining or increasing the number of platelets in the blood in a cancer patient undergoing chemotherapeutic treatment for cancer, comprising administering to said patient an effective treatment amount of Product R.  
     
     
         10 . The method of  claim 9  in which said cancer patient does not have basal cell carcinoma or a cancer of a lymphocytic cell.  
     
     
         11 . The method of  claim 9  or  10  in which said administering is not subcutaneous, intralesional, topical or by injection.  
     
     
         12 . The method of  claim 9  in which said administering to said patient is parenterally and said Product R is in a sterile injectable formulation.  
     
     
         13 . The method of  claim 12  in which said cancer patient does not have basal cell carcinoma or a cancer of a lymphocytic cell.  
     
     
         14 . The method of  claim 9  in which an effective treatment amount of Product R is in a range from about 5 microliters to about 40 microliters per kilogram of body weight per day in a sterile formulation.  
     
     
         15 . The method of  claim 9  in which an effective treatment amount of Product R is in a range from about 10 microliters to about 25 microliters per kilogram of body weight per day in a sterile formulation.  
     
     
         16 . The method of  claim 9  in which an effective treatment amount of Product R is about 30 microliters per kilogram of body weight per day in a sterile injectable formulation for about one week, followed by about 15 microliters per kilogram of body weight per day in a sterile formulation.  
     
     
         17 . A method of reducing gastric-intestinal toxicity in a cancer patient resulting from an anti-cancer chemotherapeutic agent comprising administering to said patient an effective treatment amount of Product R.  
     
     
         18 . The method of  claim 17  in which said cancer patient does not have basal cell carcinoma or a cancer of a lymphocytic cell.  
     
     
         19 . The method of  claim 17  or  18  in which said administering is not subcutaneous, intralesional, topical or by injection.  
     
     
         20 . The method of  claim 17  in which said administering to said patient is parenterally and said Product R is in a sterile injectable formulation.  
     
     
         21 . The method of  claim 20  in which said cancer patient does not have basal cell carcinoma or a cancer of a lymphocytic cell.  
     
     
         22 . The method of  claim 17  in which an effective treatment amount of Product R is in a range from about 5 microliters to about 40 microliters per kilogram of body weight per day in a sterile formulation.  
     
     
         23 . The method of  claim 17  in which an effective treatment amount of Product R is in a range from about 10 microliters to about 25 microliters per kilogram of body weight per day in a sterile formulation.  
     
     
         24 . The method of  claim 17  in which an effective treatment amount of Product R is about 30 microliters per kilogram of body weight per day in a sterile injectable formulation for about one week, followed by about 15 microliters per kilogram of body weight per day in a sterile formulation.  
     
     
         25 . A pharmaceutical composition comprising an effective treatment amount of Product R, an anti-cancer chemotherapeutic agent, and a pharmaceutically acceptable carrier  
     
     
         26 . A kit comprising a first container which contains an effective treatment amount of Product R; and a second container which contains an anti-cancer chemotherapeutic agent.  
     
     
         27 . The kit of  claim 26  further comprising a needle or syringe.

Join the waitlist — get patent alerts

Track US2007141044A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.